Discuss Cytokinetics Inc.
Cytokinetics Inc.
WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
49,80 €
0,40 %
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Raymond James from $63.00 to $92.00. They now have an "outperform" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Mizuho from $80.00 to $103.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $108.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $94.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $107.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Mizuho from $103.00 to $99.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $86.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $108.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $94.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $108.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $107.00 to $106.00. They now have an "outperform" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $94.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Needham & Company LLC from $108.00 to $72.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Raymond James from $92.00 to $70.00. They now have an "outperform" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Barclays PLC from $100.00 to $95.00. They now have an "overweight" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at HC Wainwright from $94.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at Truist Financial Co. from $86.00 to $70.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at B. Riley from $122.00 to $92.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at JPMorgan Chase & Co. from $77.00 to $65.00. They now have an "overweight" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in California Resources Corp diskutieren